Study wrapper · #1026
Pharmacologic Treatments for MASLD: A Review of Efficacy and Safety Considerations.
Newsome JS The Journal of pharmacy technology : jPT. 2026.
DOI: 10.1177/87551225261466571PubMed: 42483637
Editor's note
A narrative review of pharmacologic options for MASLD/MASH in which semaglutide is highlighted, alongside resmetirom, as having among the most consistent evidence for histologic improvement including fibrosis reduction. As a narrative review of eighteen sources, it summarizes rather than pools existing trial data. It offers a useful positioning of semaglutide within the broader metabolic liver disease treatment landscape.
Plain-language abstract
This review compares drug options for fatty liver disease and reports that semaglutide, alongside resmetirom, has the most consistent evidence for improving liver inflammation and fibrosis. Other agents showed more limited or mixed results.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026